0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV11.35%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
GT Biopharma Stock Discussion
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company, has announced FDA clearance for its Investigational New Drug (IND) application for GTB-3650, a novel NK cell engager targeting CD33+ leukemia. The Phase 1 trial for GTB-3650 is set to begin in the second half of 2024, with initial clinical data expected...
GT Biopharma, Inc. (NASDAQ: GTBP) recently announced a major development with the entry into definitive securities purchase agreements for a registered direct offering priced at-the-market under Nasdaq rules. The company disclosed that it has secured the purchase and sale of 740,000 shares of its common stock at...
$Cue Health(HLTH.US)$ UPUPUPUP
should be dropping to offering price 4.35
NEWS
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
No comment yet